Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 261

Similar articles for PubMed (Select 18328816)

1.

Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism.

Yoshimizu M, Tajima Y, Matsuzawa F, Aikawa S, Iwamoto K, Kobayashi T, Edmunds T, Fujishima K, Tsuji D, Itoh K, Ikekita M, Kawashima I, Sugawara K, Ohyanagi N, Suzuki T, Togawa T, Ohno K, Sakuraba H.

Clin Chim Acta. 2008 May;391(1-2):68-73. doi: 10.1016/j.cca.2008.02.014. Epub 2008 Feb 17.

PMID:
18328816
2.

Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones.

Tajima Y, Saito S, Ohno K, Tsukimura T, Tsujino S, Sakuraba H.

J Hum Genet. 2011 Jun;56(6):440-6. doi: 10.1038/jhg.2011.36. Epub 2011 Apr 7.

PMID:
21471980
3.

Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.

Sugawara K, Tajima Y, Kawashima I, Tsukimura T, Saito S, Ohno K, Iwamoto K, Kobayashi T, Itoh K, Sakuraba H.

Mol Genet Metab. 2009 Apr;96(4):233-8. doi: 10.1016/j.ymgme.2008.12.017. Epub 2009 Jan 31.

PMID:
19181556
4.

Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.

Parenti G, Zuppaldi A, Gabriela Pittis M, Rosaria Tuzzi M, Annunziata I, Meroni G, Porto C, Donaudy F, Rossi B, Rossi M, Filocamo M, Donati A, Bembi B, Ballabio A, Andria G.

Mol Ther. 2007 Mar;15(3):508-14. Epub 2007 Jan 9.

PMID:
17213836
5.

Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors.

Rawlings AJ, Lomas H, Pilling AW, Lee MJ, Alonzi DS, Rountree JS, Jenkinson SF, Fleet GW, Dwek RA, Jones JH, Butters TD.

Chembiochem. 2009 Apr 17;10(6):1101-5. doi: 10.1002/cbic.200900025.

PMID:
19294724
6.

Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.

Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ.

Mol Genet Metab. 2007 Jan;90(1):49-57. Epub 2006 Nov 13.

PMID:
17095274
7.

The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.

Flanagan JJ, Rossi B, Tang K, Wu X, Mascioli K, Donaudy F, Tuzzi MR, Fontana F, Cubellis MV, Porto C, Benjamin E, Lockhart DJ, Valenzano KJ, Andria G, Parenti G, Do HV.

Hum Mutat. 2009 Dec;30(12):1683-92. doi: 10.1002/humu.21121.

PMID:
19862843
8.

Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase".

Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M, Tsukimura T, Ikekita M, Tsujino S, Tsuji A, Edmunds T, Sakuraba H.

J Hum Genet. 2007;52(11):898-906. Epub 2007 Sep 6.

PMID:
17805474
9.

Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.

Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL.

J Biol Chem. 2007 Sep 28;282(39):29052-8. Epub 2007 Jul 31.

10.

Novel imino sugar α-glucosidase inhibitors as antiviral compounds.

Howe JD, Smith N, Lee MJ, Ardes-Guisot N, Vauzeilles B, Désiré J, Baron A, Blériot Y, Sollogoub M, Alonzi DS, Butters TD.

Bioorg Med Chem. 2013 Aug 15;21(16):4831-8. doi: 10.1016/j.bmc.2013.03.014. Epub 2013 Mar 22.

PMID:
23582447
11.

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.

Andersson U, Reinkensmeier G, Butters TD, Dwek RA, Platt FM.

Biochem Pharmacol. 2004 Feb 15;67(4):697-705.

PMID:
14757169
12.

Imino sugars are potent agonists of the human glucose sensor SGLT3.

Voss AA, Díez-Sampedro A, Hirayama BA, Loo DD, Wright EM.

Mol Pharmacol. 2007 Feb;71(2):628-34. Epub 2006 Nov 16.

13.

Iminosugar glycosidase inhibitors: structural and thermodynamic dissection of the binding of isofagomine and 1-deoxynojirimycin to beta-glucosidases.

Zechel DL, Boraston AB, Gloster T, Boraston CM, Macdonald JM, Tilbrook DM, Stick RV, Davies GJ.

J Am Chem Soc. 2003 Nov 26;125(47):14313-23.

PMID:
14624580
14.

Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.

Alfonso P, Pampín S, Estrada J, Rodríguez-Rey JC, Giraldo P, Sancho J, Pocoví M.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):268-76.

PMID:
16039881
15.

Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.

Luan Z, Higaki K, Aguilar-Moncayo M, Ninomiya H, Ohno K, García-Moreno MI, Ortiz Mellet C, García Fernández JM, Suzuki Y.

Chembiochem. 2009 Nov 23;10(17):2780-92. doi: 10.1002/cbic.200900442.

PMID:
19830760
16.

Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease.

Sugawara K, Saito S, Sekijima M, Ohno K, Tajima Y, Kroos MA, Reuser AJ, Sakuraba H.

J Hum Genet. 2009 Jun;54(6):324-30. doi: 10.1038/jhg.2009.32. Epub 2009 Apr 3.

PMID:
19343043
17.

Acid alpha-glucosidase deficiency (Pompe disease).

Fukuda T, Roberts A, Plotz PH, Raben N.

Curr Neurol Neurosci Rep. 2007 Jan;7(1):71-7. Review.

PMID:
17217857
18.

Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton.

Sou S, Mayumi S, Takahashi H, Yamasaki R, Kadoya S, Sodeoka M, Hashimoto Y.

Bioorg Med Chem Lett. 2000 May 15;10(10):1081-4.

PMID:
10843222
19.

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.

Butters TD, Dwek RA, Platt FM.

Glycobiology. 2005 Oct;15(10):43R-52R. Epub 2005 May 18. Review.

20.

Stabilising normal and mis-sense variant alpha-glucosidase.

Kakavanos R, Hopwood JJ, Lang D, Meikle PJ, Brooks DA.

FEBS Lett. 2006 Aug 7;580(18):4365-70. Epub 2006 Jul 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk